CliffBio
biologic

Rolvedon

eflapegrastim-xnst

Loss of exclusivitySeptember 2034projected — 12-year biologic exclusivity estimate
CompanyAssertio Specialty Pharmaceuticals, LLC

Drug detail

Brand nameRolvedon
Active ingredienteflapegrastim-xnst
Strength13.2MG/0.6ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.